NSEUpdates24 Jul 2026 · 24 Jul 2026, 08:55 pm

Updates

Piramal Pharma Limited · PPLPHARMA

✦ AI SummaryRegulatory

Piramal Pharma Limited has temporarily suspended operations at its manufacturing facilities in Ahmedabad, Gujarat, due to heavy rainfall and flooding. The company has initiated actions to assess the situation and resume operations safely. The affected facilities account for less than 3% of the company's consolidated revenues.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Please refer attachment.

Attachments (1)

📄

PIRAMALPHARMA_24072026205512_Reg30IntimationAhmedabadoperationalimpact.pdf

pdf

Download →
View document text
24 July, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Temporary suspension of operations at Company’s facilities located at Ahmedabad, Gujarat Dear Sir / Madam, This is to inform that due to exceptionally heavy rainfall and flooding across parts of Gujarat resulting in waterlogging, the operations at the Company's manufacturing facilities located at Plot Nos. 18 and 19 – PHARMEZ - Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, NH 8A, Taluka Sanand, Ahmedabad - 382 213, Gujarat, India, have been temporarily suspended as a precautionary measure. All employees, including contract staff, at the affected facilities are safe. The Company has initiated necessary actions to assess the condition of the facilities and to facilitate a safe and orderly resumption of operations at the earliest. The extent of the impact, if any, on assets, operations is currently under evaluation. Subject to the improvement in the weather conditions, the operations are expected to gradually normalize over the next few days. The assets at the affected facilities are adequately covered under the Company's insurance policies. For context, the aforesaid facilities together account for less than 3% of the Company's consolidated revenues. The Company shall provide further updates, including any material developments or financial implications, as appropriate. This is for your information and records Thanking you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400070, Maharashtra, India T +91 22 3802 3000 / 4000 Piramalpharma.com